Risk of Nonlocal Complications: Connective Tissue Diseases and Rheumatologic Illness
| Complication/Time point . | Number of events (cumulative) . | Kaplan-Meier risk . | 95% CI . |
|---|---|---|---|
| Primary breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | ||
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Revisional breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Complication/Time point . | Number of events (cumulative) . | Kaplan-Meier risk . | 95% CI . |
|---|---|---|---|
| Primary breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | ||
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Revisional breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
aRheumatologic and connective tissue diseases include rheumatoid arthritis, systemic lupus erythematosus, discoid lupus, scleroderma, vasculitis, dermatomyositis, Raynaud's phenomenon, Sjogren's syndrome, CREST syndrome, carpal tunnel syndrome, multiple sclerosis–like syndrome, multiple myeloma–like syndrome, chronic fatigue syndrome, fibromyalgia. CI, confidence interval.
Risk of Nonlocal Complications: Connective Tissue Diseases and Rheumatologic Illness
| Complication/Time point . | Number of events (cumulative) . | Kaplan-Meier risk . | 95% CI . |
|---|---|---|---|
| Primary breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | ||
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Revisional breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Complication/Time point . | Number of events (cumulative) . | Kaplan-Meier risk . | 95% CI . |
|---|---|---|---|
| Primary breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | ||
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Revisional breast augmentation | |||
| Rheumatic disease, anya | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Rheumatoid arthritis | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Systemic lupus | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
| Other rheumatologic | |||
| Week 6 | 0 (0) | — | |
| Year 1 | 0 (0) | — | |
| Year 2 | 0 (0) | — | |
| Year 3 | 0 (0) | — | |
aRheumatologic and connective tissue diseases include rheumatoid arthritis, systemic lupus erythematosus, discoid lupus, scleroderma, vasculitis, dermatomyositis, Raynaud's phenomenon, Sjogren's syndrome, CREST syndrome, carpal tunnel syndrome, multiple sclerosis–like syndrome, multiple myeloma–like syndrome, chronic fatigue syndrome, fibromyalgia. CI, confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
